Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma

Molecular Endocrinology

Volumn 26, Issue 9, 2012, Pages 1603-1616

  Garofalo, Cecilia ^a   Mancarella, Caterina ^a   Grilli, Andrea ^a   Manara, Maria Cristina ^a   Astolfi, Annalisa ^b   Marino, Maria Teresa ^a   Conte, Alexia ^c   Sigismund, Sara ^c   Carè, Alessandra ^d   Belfiore, Antonino ^e   Picci, Piero ^a   Scotlandi, Katia ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AVE 1642; FIGITUMUMAB; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; NVP AEW 541; ONCOPROTEIN; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR;

ANGIOGENESIS; ANTIGEN PRESENTATION; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DEGRADATION; DRUG MECHANISM; ENDOCYTOSIS; EWING SARCOMA; GENE CONTROL; GENE EXPRESSION; INTERNALIZATION; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INSULIN-LIKE GROWTH FACTOR II; PYRIMIDINES; PYRROLES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SARCOMA, EWING; SIGNAL TRANSDUCTION;

MURINAE;

EID: 84865585349     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1142     Document Type: Article

References (51)

1. Pollak M 2007 Insulin-like growth factor-related signaling and cancer development. Recent Res Cancer Res 174:49-53
2. Samani AA, Yakar S, LeRoith D, Brodt P 2007 The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20-47
3. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278-3288
4. Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, De Stefano F, Cuscito M, De Fazio M, Memeo V, Neri V, Cignarelli M, Giorgino R, Giorgino F 2006 Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes 55:952-961
5. Laviola L, Natalicchio A, Giorgino F 2007 The IGF-I signaling pathway. Curr Pharm Des 13:663-669
6. Siddle K 2011 Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 47:R1-R10
7. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R 2009 Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623
8. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P 2010 Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11:129-135
9. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schue-tze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH 2011 R1507, a monoclonal antibody to the insulinlike growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol 29: 4541-4547
10. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D 2010 Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 107:10791-10798
11. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, Lopez-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K 2011 Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30:2730-2740
12. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR 2010 Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 9:2652-2664
13. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, ChenJ, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A, Carboni JM 2009 The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69:161-170
14. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM, Erlichman C 2008 HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 7:2589-2598
15. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV 2010 Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 16:4654-4665
16. Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O 2009 Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15:5445-5456
17. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C 2010 Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Gene Chromosome Cancer 49:40-51
18. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD 2005 Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073
19. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, Garcia-Echeverria C, Hofmann F, Picci P 2005 Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65:3868-3876
20. Ginzinger DG 2002 Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hema-tol 30:503-512
21. Garofalo C, Sisci D, Surmacz E 2004 Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin Cancer Res 10:6466-6475
22. Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL, Picci P, Scotlandi K 2010 CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest 120:668-680
23. Benjamini YH, Hochberg Y 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57:289-300
24. Edgar R, Domrachev M, Lash AE 2002 Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207-210
25. Kanehisa M, Goto S 2000 KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30
26. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G 2000 Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 25:25-29
27. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J 2005 BABELOMICS: a suite ofweb tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res 33:W460-W464
28. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, LeharJ, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Hous-tis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC 2003 PGC-1a-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273
29. Gualberto A 2010 Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 10:575-585
30. Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D 2009 Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat 114:277-285
31. Broussas M, Dupont J, Gonzalez A, Blaecke A, Fournier M, Cor-va'ia N, Goetsch L 2009 Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int J Cancer 124:2281-2293
32. Belfiore A, Malaguarnera R 2011 The insulin receptor and cancer. Endocr Relat Cancer 18:R125-R147
33. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D 2006 Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulinlike growth factor therapy in breast cancer. Cancer Res 66:23912402
34. Polo S, Di Fiore PP 2006 Endocytosis conducts the cell signaling orchestra. Cell 124:897-900
35. Martins AS, Ordonez JL, Amaral AT, Prins F, Floris G, Debiec-Rychter M, Hogendoorn PC, de Alava E 2011 IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocy-tosis. PloS one 6:e19846
36. Sorkin A, Goh LK 2009 Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315:683-696
37. Giudice J, Leskow FC, Arndt-Jovin DJ, Jovin TM, Jares-Erijman EA 2011 Differential endocytosis and signaling dynamics of insulin receptor variants IR-A and IR-B. J Cell Sci 124:801-811
38. Sacco A, Morcavallo A, Pandini G, Vigneri R, Belfiore A 2009 Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology 150:3594-3602
39. Huang HJ, Angelo LS, RodonJ, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R 2011 R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PloS one 6:e26060
40. Gallagher EJ, LeRoith D 2011 Minireview: IGF, insulin, and cancer. Endocrinology 152:2546-2551
41. Hopkins A, Crowe PJ, Yang JL 2010 Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 136:639-650
42. Hixon ML, Paccagnella L, Millham R, Perez-Olle R, Gualberto A 2010 Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trial 5:189-208
43. Boucher J, Tseng YH, Kahn CR 2010 Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J Biol Chem 285:17235-17245
44. Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, Lewis Phillips GD, Luis E, Cavet G, Hu X, Amler LC, Lackner MR 2009 Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 8:2110-2121
45. Mukohara T, Shimada H, Ogasawara N, Wanikawa R, Shimo-mura M, Nakatsura T, Ishii G, ParkJO, Janne PA, Saijo N, Minami H 2009 Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett 282:14-24
46. Hendrickson AW, Haluska P 2009 Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr Opin Invest Drug 10:1032-1040
47. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, Helman LJ 2008 Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68:8039-8048
48. Baserga R 2009 Customizing the targeting of IGF-1 receptor. Fut Oncol 5:43-50
49. Siegrist F, Ebeling M, Certa U 2011 The small interferon-induced transmembrane genes and proteins. J Interf Cytok Res 31:183-197
50. Manara MC, Perdichizzi S, Serra M, Pierini R, Benini S, Hattinger CM, Astolfi A, Bagnati R, D'Incalci M, Picci P, Scotlandi K 2005 The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 27:1605-1616
51. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS 2011 Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 71:1029-1040